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Abstract
Background: The aim of this study is to investigate the potential impact of prostate magnetic resonance imaging
(MRI) -related interreader variability on a population-based randomized prostate cancer screening trial (ProScreen).
Methods: From January 2014 to January 2018, 100 men aged 50–63 years with clinical suspicion of prostate cancer
(PCa) in Helsinki University Hospital underwent MRI. Nine radiologists individually reviewed the pseudonymized MRI
scans of all 100 men in two ProScreen trial centers. All 100 men were biopsied according to a histological
composite variable comprising radical prostatectomy histology (N = 38) or biopsy result within 1 year from the
imaging (N = 62). Fleiss’ kappa (κ) was used to estimate the combined agreement between all individual
radiologists. Sample data were subsequently extrapolated to 1000-men subgroups of the ProScreen cohort.
Results: Altogether 89% men of the 100-men sample were diagnosed with PCa within a median of 2.4 years of
follow-up. Clinically significant PCa (csPCa) was identified in 76% men. For all PCa, mean sensitivity was 79% (SD ±
10%, range 62–96%), and mean specificity 60% (SD ±22%, range 27–82%). For csPCa (Gleason Grade 2–5) MRI was
equally sensitive (mean 82%, SD ±9%, range 67–97%) but less specific (mean 47%, SD ±20%, range 21–75%).
Interreader agreement for any lesion was fair (κ 0.40) and for PI-RADS 4–5 lesions it was moderate (κ 0.60). Upon
extrapolating these data, the average sensitivity and specificity to a screening positive subgroup of 1000 men from
ProScreen with a 30% prevalence of csPCa, 639 would be biopsied. Of these, 244 men would be true positive, and
395 false positive. Moreover, 361 men would not be referred to biopsy and among these, 56 csPCas would be
missed. The variation among the radiologists was broad as the least sensitive radiologist would have twice as many
men biopsied and almost three times more men would undergo unnecessary biopsies. Although the most sensitive
radiologist would miss only 2.6% of csPCa (false negatives), the least sensitive radiologist would miss every third.
Conclusions: Interreader agreement was fair to moderate. The role of MRI in the ongoing ProScreen trial is crucial
and has a substantial impact on the screening process.
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Background
Early detection of aggressive prostate cancer (PCa) remains
challenging. Prostate-specific antigen (PSA) -based screen-
ing reduces cancer-specific mortality by approximately
20% by detecting aggressive cancers at an early stage when
they can be successfully treated. However, such screening
also leads to overdiagnosis of clinically insignificant cancers
that are likely to be subsequently overtreated [1]. There-
fore, organized PCa screening has not been implemented
in Europe.
Traditionally, the standard procedure for men with a
clinical suspicion of PCa, with elevated PSA or abnormal
digital rectal examination, has been the systematic 10- or
12-core transrectal ultrasound (TRUS) -guided biopsy [2,
3]. The limitations of this approach are that some cases of
clinically significant PCa (csPCa) are not detected. In con-
trast, many cases of clinically insignificant PCa (cisPCa)
are overdiagnosed using this approach, and all men with a
clinical suspicion of PCa are required to undergo invasive
and harmful biopsy procedure [4, 5].
Multiparametric magnetic resonance imaging (mpMRI)
of the prostate and targeted biopsies of only lesions identi-
fied is a promising diagnostic pathway. A recent study by
Drost and colleagues has shown that MRI improves the
detection ratio (DR) of csPCa by 12% and decreases the
risk of cisPCa diagnosis by 30–40% compared to system-
atic biopsies in men with a suspected PCa [5]. Of men
with a clinical suspicion of PCa, roughly one-third have
negative MRI and can therefore avoid prostate biopsy [5].
Thus, the MRI pathway is an appealing tool for PCa
screening, as it may be possible to maintain the substantial
reduction in PCa mortality and yet avoid the unnecessary
biopsies and overdiagnosis of cisPCa.
However, the usefulness of MRI in a population-based
screening is highly dependent on the quality of the MRI
process (imaging and reporting) per se. The ability of MRI
to detect csPCa has improved over the past decade as the
Prostate Imaging Reporting and Data System (PI-RADS)
was introduced in 2012 [6] and has been updated twice
since then [7]. Nevertheless, several uncertainties remain, as
the interreader agreement on PI-RADS categories is mod-
erate at best and the experience of an individual radiologist
may have an effect on the specificity of reporting [8].
The aim of our study is to evaluate the potential impact
of MRI -related interreader variability in an ongoing ProSc-
reen PCa screening trial. We initiated a population-based
prospective randomized screening trial (ProScreen) in 2018,
which is still ongoing. In ProScreen men with a suspicion
of csPCa in a biochemical screening test (PSA and the four
kallikrein test (4 K) (free PSA, intact and total PSA and
kallikrein-like peptidase 2 [hK2]) are referred to mpMRI
with targeted biopsies of the visual lesion(s) only [9].
The precision of the ProScreen trial at detecting csPCa
while avoiding overdiagnosis, ultimately depends on the
subjective evaluation of the MRI by the radiologist. In
this current study, we specifically investigated the poten-
tial impact of prostate MRI-related interreader variability
on the ProScreen trial.
Methods
The ProScreen trial is a population-based screening trial
with a total of 67,000 men aged 50–63 years who reside in
Helsinki or Tampere in Finland that commenced in 2018
[9]. These men are randomized to either a screening arm
or a control arm in a 1:3 ratio. The men in the screening
arm are invited to consent for the trial and upon giving
their informed consent, a serum PSA test is taken,
whereas the men in the control arm will not be contacted.
A PSA ≥ 3.0 μg/l value is considered abnormal and will
trigger the next stage of screening, i.e. 4 K score test [10].
Men with a 4 K score ≥ 7.5% are referred for prostate MRI
in one of the participating urology departments. Men with
lesions that have a PI-RADS of 3–5 upon MRI are then in-
vited for transrectal ultrasound guided fusion biopsies
(FBx) of the target lesions only. Men with negative MRI
are invited for TRUS guided systematic 12-core biopsies
only when PSA density is ≥0.15 μg/l.
Here, we chose a retrospective sample of 100 non-
consecutive men who had been referred to the Helsinki
University Hospital (HUS) for suspicion of PCa before the
initiation of the ProScreen trial to come up with different
GGG classes of roughly equal size. Previous MRI or nega-
tive biopsies were allowed. Men had varying baseline risks
for PCa. Most men (n = 91) had undergone MRI before
diagnostic biopsies, whereas for nine men the MRI was
used post-biopsy in cancer staging before definitive treat-
ment. The 91 men were biopsied within 6 months of the
MRI. The mean age at imaging was 67 years (SD ±9) and
the median PSA level was 9.4 μg/l (interquartile range
[IQR] 6.7–14.5 μg/l).
The imaging was performed with 3 T scanners Philips
Achieva (from 2014) and with Siemens Skyra (from 2017).
The protocol included T2 weighted imaging (T2WI), diffu-
sion (DWI) with ADC-mapping and dynamic contrast en-
hancement (DCE). Surface coil was used and the slice
thickness was 3mm for T2WI and DWI, and 4mm for
DCE. The image resolutions for T2WI were 0,6 × 0,6mm
(Skyra) or 0,6 × 0,7 (Achieva). ADC-maps were calculated
from diffusion b-values 0 (Achieva) or 50 (Skyra), 100 and
800. The high b-value images, b2000, for tumour detection
were scanned separately (Achieva) or extrapolated up to
b1600 by using lower b-value data (Skyra). DCE imaging
comprised intravenous administration of gadolinium-based
contrast agent (Dotarem®, 0,2ml/kg, 2ml/s) with the tem-
poral resolution of 7 s (Skyra) or 8 s (Achieva) up to 2min
30 s, and flip angle 12° (Skyra) or 10° (Achieva). The pos-
sible early enhancement was assessed visually, and the data
were further processed by using scanner’s software (until
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2015) or DynaCad to create signal intensity curves of sus-
pected lesions (Fig. 1). Until October 2017 only summary
reports of the DCE analyses were stored as jpg-
images. These could not be pseudonymized ad-
equately. Hence, for the re-evaluation in the present
study, the original DCE data were not available. MRI
images were first pseudonymized. Subsequently, the
images of all 100 men were each made available to
all nine radiologists that were concurrently reporting
prostate MRI in the two ProScreen trial centers. Pre-
vious experience of the nine radiologists regarding
prostate MRI reads varied from 40 to 100 reads (one
radiologist) to 100–300 reads (one radiologist) to >
500 reads (seven radiologists) (see Table 1). The PSA
concentration, the age of the patient and the 4 K
score data were the only additional data the radiolo-
gists had during assessment. The radiologists were
blind to all other relevant data regarding the patients
of the sample. The MRI scans were evaluated using
version 2 PI-RADS [11] but the DCE image sets were
not available, thus the re-evaluation is based on only
biparameric MRI (bpMRI).
Structured pathological assessment was given using the
five-tier Gleason Grade Groups (GGG): 3 + 3; 3 + 4; 4 + 3;
4 + 4 and > 8 [12]. We focused on the evaluation of the
index lesion, which was defined as the largest and highest-
grade lesion in the prostate [13]. The gold standard in sen-
sitivity and specificity analyses was a histological compos-
ite variable: radical prostatectomy histology (for those who
underwent radical prostatectomy, n = 38) or biopsy result
within 1 year from the imaging (for those who did not
undergo radical prostatectomy, n = 62). As the positive
predictive value (PPV) and negative predictive value
(NPV) are highly dependent on the underlying prevalence
of the condition, we also report positive and negative like-
lihood (LH) ratios.
Fleiss’ kappa was used to estimate the combined agree-
ment between all individual radiologists. Finally, the dis-
tribution of PI-RADS score was presented graphically
for each patient stratified by composite pathological re-
sult. The study protocol was evaluated by the research
ethics committee of the HUS Helsinki University Hos-
pital (HUS/333/2019).
Results
The median follow-up time for men with negative
MRI or negative biopsies was 2.4 years (range 1.5–5.4
years and mean 2.6 years, SD ±0.82 years). Twenty-
two men (22%) had both targeted and standard 12-
core biopsies, 68 men (68%) had only targeted
biopsies, nine (9%) men had only standard 12-core
biopsies and one man had saturation biopsies. Most
men (n = 87, 87%) had PCa upon biopsy. Of the 13
men (13%) with benign biopsy, two (15.4%) were later
diagnosed with PCa. Of these two, one had GGG1
cancer diagnosed by transurethral resection of the
prostate and the other one had GGG2 cancer diag-
nosed by subsequent saturation biopsies.
Of the 89 men diagnosed with PCa, 13 (14.6%) had
GGG1 cancer, 31 (34.8%) had GGG2 cancer, 28
(31.5%) had GGG3 cancer, 7 (7.9%) had GGG4 cancer
and 10 (11.2%) had GGG5 cancer in the biopsies.
Thus, 76% of the patients in the cohort sample had
clinically significant cancer (GGG2 or worse) and
roughly half had GGG3 cancer or worse. Patient level
assessments grouped by pathological result are illus-
trated in Fig. 2.
Fig. 1 Prostate MRI images from two patients demonstrating poor agreement (images a-d) and good agreement (images e-h). T2 (a and e), T2
with delineated lesion (b and f), ADC (c and g) and high b (d and h) images are shown. In a 64-year old man with PSA of 22 ng/ml (a-d) five
radiologist scored a lesion and four did not (fusion biopsies were benign and no PCa has been diagnosed during a 2.5-year follow-up). In a 72-
year old man with PSA of 10.5 ng/ml all nine radiologist correctly scored a lesion (GG5 in fusion biopsies)
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Agreement between radiologists
Individual radiologists reported a PI-RADS 3–5 index le-
sion in 75% of cases (range 57–93%) (Table 1). Agree-
ment among radiologists was fair (Fleiss’ kappa 0.40).
Agreement was moderate (Fleiss’ kappa 0.60) for PI-
RADS 4–5 lesions, which were found in 61% of cases
(range 48–75%) (Table 1). T3–4 disease was reported in
26% of cases (range 16–38%) and agreement among ra-
diologists was moderate (Fleiss’ kappa 0.49) (Table 1).
Radiological assessment compared to the pathological
reference
The radiological assessment compared to the patho-
logical reference is presented in Table 2. Mean positive
Table 1 Comparison of radiological findings and agreement between individual radiologists and clinical reference
Fig. 2 The number of radiologists identifying PIRADS 3–5 index lesion
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and negative LR was 2.0 (SD ±1.1, range 1.1–4.0) and
0.4 (SD ±0.2, range 0.2–0.7), respectively.
For more suspicious lesions (PI-RADS 4–5 index le-
sion, any PCa) (Table 2b), corresponding positive and
negative LR median was 4.2 (SD ±3.0, range 0–7.9) and
0.4 (SD ±0.1, range 0.3–0.5), respectively.
For clinically significant PCa (GGG2–5) and PI-RADS
3–5 index lesion (Table 2c), corresponding median and
mean positive and negative LR was 1.5 (SD ±0.6, range
1.2–2.7 and 0.4 (SD ±0.1, range 0.1–0.5), respectively.
Positive and negative LR was 2.8 (SD ±2.1, range 1.5–
8.9) and 0.4 (SD ±0.1, range 0.3–0.5), respectively, for
PI-RADS 4–5 lesions in finding csPCa (Table 2d).
Seven of the nine radiologists were very experienced
with prostate MRI assessment and therefore no com-
parative statistical analysis on experience level was
done.
Extrapolation to the screening cohort
In the ProScreen trial approximately 16,700 men are
randomized to the screening arm. A power calculation
determined that roughly 11,690 men would be expected
to participate in screening (70%) and of these, 1520 men
would have PSA ≥ 3.0 μg/l and subsequently 1000 men
would have a 4KScore of ≥7.5% and would therefore
have the indication for prostate MRI [9].
Assuming a 30% prevalence of csPCa in the screen-
positive subcohort with 1000 men, the mean sensitivity
(82%) and specificity (47%) of radiologists would entail 639
men being referred to biopsy of which 244 men would be
true positive and 395 false positive. Of the 361 men who
would not be referred to biopsy, 305 would be true
negatives and 56 would harbor a cancer that would be
missed, i.e., false negative.
If the sensitivity and specificity of the evaluations done
by the most sensitive radiologist is assumed in a similar
subcohort of 1000 men, 846 men would be biopsied
(292 true positive; 554 false positive) and 154 men would
not be biopsied (146 true negative; 8 false negative).
Conversely, if the sensitivity and specificity of the eval-
uations carried out by the least sensitive radiologist is
extrapolated into the same subcohort of 1000 men, 376
men would be biopsied (of which 201 would be true
positive; 175 false positive) and 624 men would not be
biopsied (525 true negative; 99 false negative).
Discussion
We estimated the impact of interreader variability on our
ongoing ProScreen PCa screening trial which, in addition
to the two objective biomarker measurements (PSA and 4
K), is ultimately dependent on subjective evaluation of the
MRI by the radiologist. Even though our results corres-
pond reasonably well to the published data [4, 5, 8], the
range between the radiologists is broad. We observed a
significant difference between radiologists in sensitivity
and specificity which can have a substantial impact on the
precision of the screening. Assuming a 30% prevalence for
csPCa in screen positive men, twice as many men would
be biopsied based on MRI interpretation by the most sen-
sitive radiologist compared to the least sensitive radiolo-
gist and almost three times more men would undergo
unnecessary biopsies (i.e. due to false positive screening
results). Conversely, the most sensitive radiologist would
miss only 2.6% of csPCa (false negatives), whereas the least
Table 2 Sensitivity, specificity, positive predictive value and negative predictive value for PIRADS 3–5 or PIRADS 4–5 index lesions
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sensitive radiologist would miss every third case. On aver-
age 64% of men would be biopsied and 62% of them
would undergo unnecessary biopsy but every fifth man
with csPCa would be missed.
We could not evaluate the explanatory factors for the
observed variation between radiologists, although the radi-
ologists’ experience of prostate MRI readings were col-
lected. However, the majority (seven out of nine
radiologists) were very experienced, which prevented us
from comparing the impact of experience (Table 1). Inter-
estingly, a recent study that evaluated MRI-related inter-
reader variability reported that the sensitivity for detection
of index lesion was not dependent on radiologist experi-
ence, whereas the specificity was highly dependent on
reader experience [8]. Therefore, other causal factors of
interreader variability might also exist. It can be assumed
that the extremes (clearly malignant and clearly benign)
would be reported more consistently although the area in-
between these extremes would be more prone to interrea-
der variability. This is at least in part supported by our
data as most of the radiologists correctly identified GGG
4–5 cancers whereas there was substantial variability for
men with cisPCa as none of the benign prostates were
correctly identified by all the radiologists (Fig. 2). Such
high variability leads to unnecessary biopsies and, thus,
causes unnecessary morbidity and elevated costs.
We found fair interobserver agreement for the detection
of index lesion (0.40) and moderate agreement (0.60) for
the detection of PI-RADS 4–5 index lesion. While similar
relatively modest agreement has been observed previously
by Baldisserotto et al. (interobserver agreement of 0.53)
[14] we were expecting better agreement [15, 16]. Greer
et al. evaluated the interobserver agreement for five radiolo-
gist and found a high interobserver agreement [15].
Girometti et al. found substantial agreement in assessing
PCa with category three or greater [16]. Greer et al. [8] re-
ported excellent agreement (0.87) for detecting index lesion
and substantial agreement (0.74) for true-positive findings.
In that same study, nine radiologists evaluated on average
58 MRIs from a group of 163 patients of whom 110 (67%)
had a subsequent radical prostatectomy as a reference
standard. This might explain their better observed agree-
ment as men selected for RP are more likely to harbor large
csPCa. Furthermore, Greer and colleagues noted that not
all radiologists interpreted all the images. Similar to the
study by Greer et al., biopsy information was not available
by the radiologists in our present study. In addition, the in-
terpretation in our study was based on bpMRI as DCE was
not available for the radiologists. It has been suggested that
readers have a high level of agreement on DCE-MRI assess-
ment in general [17] although agreement regarding the per-
ipheral zone lesions on DCE images may be compromised
[18]. It is anticipated that PI-RADS v2.1 will decrease the
interreader variation in DCE MRI analyses and reduce
overinterpretations compared to PI-RADS v2 [19]. It has
also been reported that DCE may assist in the detection of
csPCa in both the peripheral zone (PZ) and the transi-
tional zone (TZ) [17, 20]. Therefore, we expect that the
agreement in the ProScreen trial would be better as radiol-
ogists that interpret the MRIs of screen positive men in
practice have the opportunity to consult colleagues on dif-
ficult cases and may have some benefit to evaluating DCE
in men with equivocal peripheral zone lesions according
to PI-RADS. On the other hand, concern regarding gado-
linium deposition in the brain and the extra scanner time
(i.e. costs) needed for DCE may promote the use of
bpMRI [21]. Also, unknown factors could influence
mpMRI interpretation, other than reader experience, and
that this needs to be investigated in further studies. Even-
tually, further standardization in the parameters used for
imaging may improve consistency of reporting.
Some evident discrepancies with radiological and patho-
logical assessment were seen in our study (see Fig. 1). A
man with a large GG3 pT3a cancer in prostatectomy spe-
cimen was correctly identified in MRI by only one of nine
radiologists. Conversely, a man with only benign inflam-
matory histology in biopsies was erroneously scored as
cancer by all but one radiologist. These cases aptly dem-
onstrate the inability of prostate MRI to detect some 7%
of the csPCas correctly, whereas it is well known that in-
flammatory changes may confound a reading by appearing
suspicious in prostate MRI and is a common cause for
false positives [4, 22, 23].
Currently, substantial uncertainty remains about the ap-
propriate actions to be taken on men with clinical suspi-
cion for PCa but negative MRI (nMRI). The true false
negative rate, i.e., the rate at which csPCas are missed by
MRI, is difficult to assess. Clinically the question is
whether systematic biopsies should accompany targeted
biopsies. For proper analysis of false negative rate, pros-
tates of all men with PCa suspicion would be removed for
pathological evaluation irrespective of MRI/biopsy results,
which of course is unethical. The PROMIS trial tackled
this dilemma by taking intense 5mm template mapping
biopsies on all men. They showed a false negative rate of
12% for >GGG1 cancers and 7% for >GGG2 cancers [4].
Another way to look at this would be to rely on csPCa in-
cidence during follow-up after negative MRI. Panebianco
V et al. showed that csPCa diagnosis free survival (DFS)
was 95% after 2 years follow-up [24]. Furthermore, a re-
cent analysis from another cohort largely corroborate this
finding by reporting a csPCa DFS of 99.6% after 3 years
[25]. In terms of the ProScreen trial this is reassuring as
screen positive men (PSA > 3 and 4 K > 7.5%) with a nMRI
or negative targeted biopsy are rescreened after 2 years.
Furthermore, men with nMRI with PSAD (PSA density) >
0.15 will undergo systematic biopsies as supported by the
recent review and meta-analysis [26].
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The use of pre-biopsy MRI as a triage test criterion for
restricting biopsy to only men with suspicious lesions,
could result in one in four men avoiding biopsy. This is
in line with the data from PROMIS and PRECISION tri-
als where nMRI rates of 27 and 28% were reported [4,
27]. A recent Cochrane review reported up to one-third
of men with nMRI [5] whereas up to one in two has
been reported in some expert centers [28].
We found a moderate sensitivity for the detection of any
PCa (79%) and approximately the same sensitivity for
csPCa (ISUP GG 2–5, 81%). Even though the MRI was
quite accurate in detecting csPCa, the sensitivity for more
suspicious lesions (PI-RADS 4–5) did not improve. Other
studies have obtained better sensitivities (Cochrane review
91%, PROMIS 93%) [4, 5]. This is possibly due to differ-
ences in reference standards. The Cochrane review was
based on template-guided biopsy and the PROMIS trial
was based on 5mm template mapping biopsy as opposed
to the systematic biopsy for most men used in our study.
The specificity of the MRI for csPCa in our study was in
concordance with the Cochrane review [5].
A low NPV for cisPCa and a high PPV were found in
contrast to other studies [4, 5, 29]. The NPV and PPV
are highly dependent on the underlying prevalence of
the disease and the observed discrepancy, which prob-
ably reflects the high prevalence of csPCa (76%) in our
study cohort sample.
The threshold used to define positive MRI is equivocal
[6]. The intermediate PI-RADS 3 lesions are particularly
difficult to define [5]. If the threshold in our study was set
at PI-RADS 4 and 5 lesions instead of PI-RADS 3, the pro-
portion of men with nMRI would have increased from 25
to 39%, and the MRI would not have correctly identified
33% of csPCa. This is in concordance with the literature
[4, 8]. In respect to the ProScreen trial, it might be an ac-
ceptable compromise to increase further the ratio between
the benefit and the harm due to built-in “safety tailgate”,
whereby men with nMRI would undergo systematic bi-
opsy if PSAD > 0.15, and otherwise (PSAD < 0.15) would
be invited for the next screening round in 2 years [9].
+Some inherent limitations to our study must be con-
sidered. The PCa prevalence in our study cohort (87%) is
higher than in the general population (30%) [30, 31]. Fur-
thermore, the prevalence of csPCa was also high (76%).
The prevalence of csPCa in the Cochrane meta-analysis,
the MRI-FIRST trial and the 4M trial were 28, 38 and
30%, respectively [5, 28, 29] hence these discrepancies
largely restrict any direct comparison of the results. How-
ever, our study was not designed to assess the diagnostic
performance of MRI, thus the related limitations such as
high prevalence of the disease and verification bias are not
essential. Instead, the aim of our study was to evaluate the
interreader agreement between radiologists and extrapo-
late these to the ProScreen cohort. The agreement
between radiologists was better for the very high-risk
GGG4 and GGG5 cancers as opposed to men with benign
histology, which is reassuring in regard to mortality reduc-
tion in ProScreen. Nevertheless, the consequence is that
more benign prostates would be scored suspicious and
thus, the cost-efficiency of screening will be reduced by
the taking of unnecessary biopsies.
Though the aim and design of the study were to evalu-
ate interreader agreement, we should also pay attention
to the urologist’s role in the diagnostic work up. Accur-
acy of the fusion biopsy to detect the lesion correctly
identified by the radiologist could not be evaluated here.
Re-reading the MRI images did not entirely mimic the
routine clinical scenario for several reasons. Although
they are still of controversial importance, the DCE se-
quences were not available for the radiologists [11, 32].
Moreover, contrary to clinical routine, radiologists were
not allowed to consult a colleague with challenging
cases. These likely underestimate the interreader agree-
ment observed. Finally, nearly all radiologists were rela-
tively experienced, and therefore we had no opportunity
to study the effect of experience on the agreement di-
mension. All these factors may limit the extent to which
the results can be generalized, although they should not
have a significant effect on the ProScreen trial per se.
Conclusions
The interreader variability among radiologists whom in-
terpret prostate MRI is significant. In respect to the on-
going ProScreen PCa screening trial, the effect on
mortality reduction is expected to be modest. However,
poor interobserver agreement especially for men with
true benign histology may cause undue sampling of the
prostate and thus drive inefficacy of screening.
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